DX / Differentials / MED SPA & AESTHETICS
D-05 — PREPARING FOR SALE · MED SPA & AESTHETICS
Growth has to read as a system — med spas
Growth has to read as a system a buyer can re-run
PRESENTATION — WHAT THE OPERATOR SEES
A process is twelve to twenty-four months out and the last two years look strong. The question a private-equity buyer asks is not whether the revenue happened; it is whether it can be reproduced by somebody who does not have the founder, the best consultant, or the discount calendar.
DIFFERENTIAL — LIKELY CAUSES, MOST LIKELY FIRST
- 01
Revenue is concentrated in people rather than in a process
If the two consultants who close most of the body-contouring work leave at close, the growth story leaves with them. Buyer diligence finds this quickly, and it is priced.
Revenue by named consultant and by named injector is a query the group can run on itself before anybody else runs it.
No published distribution — ADMEN source register, /sources/
NOT THIS IF — No individual accounts for a disproportionate share of revenue in any line, and close rate is inside a narrow band across the roster.
- 02
The reporting cannot be re-run by a stranger
Definitions that live in one person's spreadsheet do not survive diligence. If a lead, a consult and a sold treatment are defined differently at different clinics, no trend line built from them is defensible.
One definition set applied identically across every clinic, with the arithmetic shown, is the deliverable. Where it does not exist, the trailing history has to be rebuilt before it can be presented.
No published distribution — ADMEN source register, /sources/
NOT THIS IF — One definition set is already applied across every clinic and the monthly pack reconciles to the income statement.
- 03
The growth was bought on discount and the margin trend says so
Revenue growth carried by a rising discount share is growth a buyer will discount in turn, because the margin trajectory is visible and the mechanism is obvious.
Discount share of revenue and gross margin per treatment, by service line, twenty-four to thirty-six months.
No published distribution — ADMEN source register, /sources/
NOT THIS IF — Discount share is flat or falling across the period and margin per treatment held.
- 04
A service line with a known margin cliff is carrying the story
Medical weight management is the current example and the cliff is a matter of public record rather than opinion. A growth narrative built on a line whose economics changed will not survive a diligence read.
The FDA declared the semaglutide shortage resolved on 21 February 2025, which removed the statutory basis for 503B outsourcing facilities to compound a copy of an approved drug. The manufacturers now sell direct to patients — NovoCare and LillyDirect both publish self-pay pricing — so a clinic charging a retail markup is quoting against a public price list.
US Food and Drug Administration, semaglutide shortage resolution, 21 February 2025; NovoCare and LillyDirect published self-pay pricing
NOT THIS IF — The line is run as a defensible-margin service with a clear role and the growth narrative does not depend on it.
HOW TO TELL THEM APART
How to tell these apart in your own numbers
Each of these is a measurement you can run yourself, without us.
01 · Revenue is concentrated in people rather than in a process
Revenue and sold-treatment count by named consultant and named injector, twenty-four months, as a share of the total and of each service line.
CONFIRMS IF
A small number of individuals carry a disproportionate share of a line.
EXCLUDES IF
Production is distributed and close rates are consistent across the roster.
02 · The reporting cannot be re-run by a stranger
Take one month and have somebody outside the finance team rebuild the pack from source systems using only the written definitions.
CONFIRMS IF
They cannot reproduce it, or they reproduce a different number.
EXCLUDES IF
It reconciles.
03 · The growth was bought on discount and the margin trend says so
Discount share of revenue and gross margin per treatment by service line, monthly, thirty-six months.
CONFIRMS IF
Revenue growth correlates with rising discount share and falling margin.
EXCLUDES IF
Margin held or improved through the growth period.
04 · A service line with a known margin cliff is carrying the story
Contribution by service line for the trailing twenty-four months, with medical weight management isolated, and the share of group growth attributable to it.
CONFIRMS IF
A material share of the growth story sits in a line whose published economics changed inside the period.
EXCLUDES IF
The line is a small, stable contributor and growth is carried elsewhere.
WHAT RESOLVES EACH
What resolves this, and how you will know it resolved
| Revenue is concentrated in people rather than in a process | Rx 05 · preparing for sale → | A growth narrative built from instrumented history rather than from assertion, with the owner-dependence and consultant-concentration questions answered before a buyer asks them. |
| The reporting cannot be re-run by a stranger | Rx 04 · marketing attribution → | One definition set across every clinic, one monthly pack, and arithmetic that reconciles to the income statement — the artefact diligence actually reads. |
| The growth was bought on discount and the margin trend says so | Rx 01 · patient acquisition → | Demand moved off promotion far enough ahead of the process that the margin trend, not the promise, is what a buyer reads. |
| A service line with a known margin cliff is carrying the story | Rx 05 · preparing for sale → | The weight-management line presented as what it is — a service with a defensible margin and a clear role — rather than as the growth engine. An agency pitching it as the category's growth story in 2026 has not read the filings. |
WHAT "RESOLVED" LOOKS LIKE — Share of revenue reproducible without a named individual, and margin trend by service line
MEDIAN
Not published. Transaction multiples in this category are not published in a form that is comparable across operators.
TOP DECILE
Not published, and a modelled multiple is a model rather than a comparable.
TARGET
Twelve to twenty-four months of history on one definition set, reconciled to the income statement, with no individual carrying a disproportionate share of a line and discount share flat or falling.
No published distribution — ADMEN source register, /sources/
HOW THIS DIFFERS BY SCALE
How this differs by scale
| Single site | A single clinic sells on the owner's own production more often than not, and that is the entire diligence conversation. |
| Group | Consultant concentration and definition drift between clinics are the two findings that most often reprice a group of this size. |
| Platform | At platform scale the buyer is buying the reporting as much as the clinics, and a pack that cannot be re-run is priced as risk. What aesthetics platform operators hand over at close is the instrumentation, and it is either legible to a stranger or it is a discount. |
OTHER PRESENTATIONS — MED SPA & AESTHETICS
- Cost per lead is falling and cost per sold treatment is not
- Consult volume is short of plan and the leads are there
- Revenue per clinic is flat while lead volume grows
- Two clinics, same brand and same offer, converting differently
A differential narrows the field. It does not replace the examination — that is what the six weeks are for. Every figure above is an industry reference range, not a client's numbers; those stay sealed. Sources are set out at /sources.
APPLY — 6 / QUARTER →